Generate Biomedicines, Roswell Park dose first patient in Phase 1 ovarian cancer trial of GB-5267 CAR-T therapy

• Generate Biomedicines launched a first-in-human Phase 1 trial of GB-5267, an “armored” CAR T-cell therapy for ovarian cancer.
• No results have been presented; the study has started dosing patients and will report safety and tolerability outcomes in the future.
• Program targets MUC16, a biomarker over-expressed in more than 80% of ovarian tumors, aiming to improve activity in solid tumors.
• Trial design seeks to avoid pre-infusion chemotherapy, positioning the approach as potentially more tolerable than standard CAR T protocols.
• Enrollment focuses on patients with disease that returned or did not respond to platinum-based chemotherapy, a high-need segment with limited options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010700PRIMZONEFULLFEED9837626) on October 01, 2026, and is solely responsible for the information contained therein.